ALERT:

Clinical Trial

General Myasthenia Gravis Clinical Trial 20213074

[LCID Study Number: 20213074]

Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravi

The purpose of this study is to evaluate the efficacy of nipocalimab compared to placebo in treating seropositive generalized myasthenia gravis (gMG).

Disease/Condition: General Myasthenia Gravis

Department: Neurology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: Tanya.L.Fennell@lahey.org

Primary Contact Phone: 781-744-2400

Clinical Trial Details

View NCT ID 04951622 on ClinicalTrials.gov

Protocol #: 20213074

Principal Investigator(s): Michal Vytopil

Study Coordinator(s): Tanya Fennell

Trial Phase: Sponsor Initiated Study Phase 3